Sam Fazeli
speaker
906 appearances
5 recordings
1 series
first heard Oct 2025
last heard 31 Mar
Sam Fazeli’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 5 in all, peaking in Mar 2026 with 2.
Appearances
Bi-specifics.
Now, we've all had bi-specifics.
We know bi-specifics.
A lot of them have been in the world of CD3 T-cell engagers.
However, the real hardcore data for bi-specifics with the idea of I've got two mechanisms of action, not CD3,
on the same cell, so TIGIT PD1, CTLA4 PD1, VEGF PD1, I mean, they all happen to be that sort of world.
Of course, we've got the ribravant from J&J in terms of CMET and EGFR that's already approved and proven, but I'm going to pitch by specifics of that elk as the proof of whether the idea of biology of it, i.e.
the
the two mechanisms on the same cell at the same time becomes a reality next year or not.
So I'm rooting for it.
I'm hopeful for it.
Not any particular one, but I quite like still the AstraZeneca revlogostomic approach, which is TIGIT PD-1.
I know that I'm probably the last man standing here and they are the last company standing pretty much.
What's yours?
Yeah, I agree.
I mean, we've got some of the more clever, well, not more clever, also interesting antibody molecule conjugates coming up, right?
People who have just been learning about folks using an anti-EGFR, for instance, or an anti-HER2 to bring a kinase inhibitor.
to the milieu, to the cells, or RNA modulators, siRNA, etc.
So that's going to be really exciting.
I just hope that the world is there and ready to remember that these drugs, at the end of the day, need to sell
Showing 481–500 of 906 · page 25 of 46
← Previous
Next →